Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials
Nivolumab-associated nausea and vomiting as an immune adverse event
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Nivolumab for the treatment of bladder cancer
Nivolumab in melanoma
Nivolumab-associated acute glomerulonephritis: a case report and literature review
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report
Nivolumab in renal cell carcinoma: latest evidence and clinical potential
Nivolumab: A Review in Advanced Melanoma
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
Nivolumab before and after allogeneic hematopoietic cell transplantation
Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation
Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Nivolumab一线治疗晚期恶性黑色素瘤的研究进展
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Nivolumab in the treatment of advanced renal cell carcinoma
Nivolumab-associated bone marrow necrosis
Nivolumab in non-small-cell lung cancer with EGFR mutation
Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Nivolumab in squamous cell carcinoma of the head and neck
Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Nivolumab in recurrent/metastatic head and neck cancers
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Nivolumab combined with ruxolitinib: antagonism or synergy?
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review
Nivulian-II a new milk clotting cysteine protease of Euphorbia nivulia latex
你往何处去?——从女性主义角度解读萧红
你往何处去——游民、游民意识与中国社会
拟万带兰和湿唇兰杂交种子胚的组织培养和植株再生